BCRX Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
Biocryst Pharmaceuticals Inc had $875M of revenue in fiscal 2025, up 94.1% on the year before. Over five years, revenue changed +117.9% a year on average.
Last close Β· Oct 23, 2026
$7.65
1.7%Hi! I read Biocryst Pharmaceuticals Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+94.1%
Yes. Sales grew 94.1% last year.
Does it make a profit?
30.2%
Yes. It keeps 30.2% of every sale as profit.
Does profit turn into cash?
39.4%
Yes. 39.4% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Biocryst Pharmaceuticals Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 6, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Jan 12, 2026 | Q4 '25 | After the market closes | 8-K β |
| Oct 14, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 4, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 5, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Jan 10, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 4, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Biocryst Pharmaceuticals Inc had $875M of revenue in fiscal 2025, up 94.1% on the year before. Over five years, revenue changed +117.9% a year on average. Its operating margin was 39.0%, up 39.5Β pts: of every 100 in sales, about 39 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Biocryst Pharmaceuticals Inc made $264M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $345M in fiscal 2025, 39.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Biocryst Pharmaceuticals Inc has $272M more cash than debt.
Cash, debt and the ratios that show how comfortably Biocryst Pharmaceuticals Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $508M | $424M | $389M | $321M | $275M |
| Debt incl. finance leases | $298M | $234M | $308M | $319M | $2.8M |
| Net debt / EBITDA | β | β | β | β | β0.8x |
| Interest coverage | β3.0x | β1.5x | β1.0x | β0.0x | 4.3x |
| Current ratio | 5.5x | 4.9x | 3.3x | 2.6x | 2.1x |
| Quick ratio | 5.3x | 4.6x | 3.1x | 2.6x | 2.0x |
| Total assets | $588M | $550M | $517M | $490M | $514M |
| Total liabilities | $695M | $845M | $972M | $966M | $633M |
| Shareholders' equity | β$107M | β$295M | β$456M | β$476M | β$119M |
| Net debt (β = net cash) | β$209M | β$190M | β$81.3M | β$2.0M | β$272M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Biocryst Pharmaceuticals Inc passes 7 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 1 / 8 | 4 / 8 | 3 / 9 | 5 / 9 | 4 / 9 | 4 / 9 | 3 / 9 | 7 / 9 |
| Accruals ratio | β1.9% | β18.4% | β5.3% | β12.0% | β18.7% | β9.1% | β15.0% | β24.6% | β7.3% | β16.6% |
| Altman Z'' | β23.23 | β10.93 | β18.03 | β16.46 | β9.26 | β3.73 | β5.90 | β8.05 | β8.82 | β2.63 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $26.4M | $25.2M | $20.7M | $48.8M | $17.8M | $157M | $271M | $331M | $451M | $875M |
| Gross profit | $24.1M | $24.0M | β | $45.1M | $16.3M | $150M | $264M | $327M | $438M | $856M |
| Research and development | $61.0M | $67.0M | $84.9M | $107M | $123M | $209M | $253M | $217M | $175M | $166M |
| Operating income | β$48.6M | β$57.4M | β$94.2M | β$99.5M | β$175M | β$178M | β$148M | β$104M | β$2.5M | $341M |
| Interest expense | $6.5M | $8.6M | $9.2M | $11.9M | $14.5M | $59.3M | $99.1M | $108M | $98.5M | $78.9M |
| Pretax income | β | β | β | β$109M | β$183M | β$182M | β$244M | β$226M | β$87.0M | $267M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $2.3M | $2.7M | $0.3M | $1.9M | $3.5M |
| Net income | β$55.1M | β$65.8M | β$101M | β$109M | β$183M | β$184M | β$247M | β$227M | β$88.9M | $264M |
| Diluted EPS | β$0.75 | β$0.78 | β$0.98 | β$940.00 | β$1.09 | β$1.03 | β$1.33 | β$1.18 | β$0.43 | $1.21 |
| Diluted shares | 0.07B | 0.08B | 0.10B | 0.12B | 0.17B | 0.18B | 0.19B | 0.19B | 0.21B | 0.22B |
| Cash flow | ||||||||||
| Cash from operations | β$53.4M | β$41.1M | β$92.6M | β$89.6M | β$135M | β$142M | β$162M | β$95.1M | β$52.0M | $347M |
| Capital expenditure | $5.3M | $0.3M | $0.4M | $0.3M | $0.5M | $2.4M | $1.4M | $2.2M | $1.1M | $2.5M |
| Free cash flow | β$58.7M | β$41.5M | β$92.9M | β$89.9M | β$136M | β$145M | β$163M | β$97.3M | β$53.1M | $345M |
| Depreciation and amortization | $0.5M | $0.7M | $0.8M | $0.7M | $0.7M | $0.8M | $1.4M | $1.7M | $1.2M | $1.4M |
| Stock-based compensation | $8.5M | $12.6M | $9.4M | $17.7M | $14.8M | $34.6M | $44.7M | $55.6M | $65.4M | $85.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $54.7M | $114M | $104M | $136M | $300M | $508M | $424M | $389M | $321M | $275M |
| Total debt | $23.0M | $23.0M | $30.0M | $50.0M | $123M | $298M | $232M | $303M | $315M | $0.0M |
| Finance lease liabilities | β | β | β | β | β | β | $2.6M | $4.4M | $4.0M | $2.8M |
| Current assets | $67.0M | $125M | $114M | $164M | $324M | $566M | $517M | $496M | $422M | $404M |
| Current liabilities | $54.4M | $74.8M | $69.5M | $92.3M | $106M | $104M | $106M | $150M | $160M | $196M |
| Inventory | $0.5M | β | $1.6M | $0.0M | $7.0M | $15.8M | $27.5M | $28.7M | $8.1M | $5.4M |
| Property and equipment, net | $9.9M | $9.5M | $9.1M | $7.3M | $7.1M | $8.7M | $8.6M | $7.9M | $7.8M | $8.8M |
| Total assets | $89.8M | $178M | $147M | $175M | $335M | $588M | $550M | $517M | $490M | $514M |
| Total liabilities | $88.3M | $94.5M | $97.6M | $137M | $354M | $695M | $845M | $972M | $966M | $633M |
| Preferred stock | $0.0M | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $1.6M | $83.8M | $49.2M | $38.3M | β$19.3M | β$107M | β$295M | β$456M | β$476M | β$119M |
| Margins | ||||||||||
| Gross margin | 91.3% | 95.5% | β | 92.4% | 91.3% | 95.4% | 97.6% | 98.6% | 97.3% | 97.8% |
| Operating margin | β184.4% | β227.9% | β456.2% | β203.7% | β981.1% | β113.1% | β54.8% | β31.3% | β0.6% | 39.0% |
| EBITDA margin | β182.6% | β225.2% | β452.5% | β202.2% | β976.9% | β112.6% | β54.3% | β30.8% | β0.3% | 39.1% |
| Net margin | β209.3% | β261.2% | β490.3% | β223.0% | β1,026.4% | β117.1% | β91.2% | β68.4% | β19.7% | 30.2% |
| FCF margin | β222.8% | β164.7% | β450.0% | β184.1% | β761.4% | β92.0% | β60.3% | β29.4% | β11.8% | 39.4% |
| Returns | ||||||||||
| Return on capital employed | β137.0% | β55.5% | β121.8% | β119.9% | β76.3% | β36.7% | β33.4% | β28.3% | β0.8% | 107.2% |
| Return on equity | β3,494.6% | β154.2% | β152.3% | β248.9% | β1,925.4% | β | β | β | β | β |
| Return on assets | β61.4% | β49.1% | β62.3% | β67.6% | β71.7% | β39.9% | β43.4% | β42.5% | β17.6% | 52.5% |
| Return on tangible equity | β3,494.6% | β78.5% | β205.7% | β284.7% | β | β | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | β4.4% | β18.0% | 136.5% | β63.5% | 782.4% | 72.3% | 22.4% | 36.0% | 94.1% |
| Share count change | β | 14.6% | 22.2% | 12.0% | 44.7% | 7.1% | 3.8% | 3.4% | 7.5% | 5.8% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β | β | β | β | β0.8x |
| Debt / equity | 14.6x | 0.3x | 0.6x | 1.3x | β | β | β | β | β | β |
| Interest coverage | β7.5x | β6.7x | β10.3x | β8.4x | β12.1x | β3.0x | β1.5x | β1.0x | β0.0x | 4.3x |
| Current ratio | 1.2x | 1.7x | 1.6x | 1.8x | 3.1x | 5.5x | 4.9x | 3.3x | 2.6x | 2.1x |
| Quick ratio | 1.2x | 1.7x | 1.6x | 1.8x | 3.0x | 5.3x | 4.6x | 3.1x | 2.6x | 2.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 20.0% | 1.3% | 1.8% | 0.7% | 2.9% | 1.5% | 0.5% | 0.7% | 0.2% | 0.3% |
| Stock comp / revenue | 32.2% | 50.1% | 45.5% | 36.3% | 83.1% | 22.0% | 16.5% | 16.8% | 14.5% | 9.7% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 1.0 | 4.0 | 3.0 | 5.0 | 4.0 | 4.0 | 3.0 | 7.0 |
| Altman Z'' | β23.2 | β10.9 | β18.0 | β16.5 | β9.3 | β3.7 | β5.9 | β8.1 | β8.8 | β2.6 |
| Accruals ratio | β1.9% | β18.4% | β5.3% | β12.0% | β18.7% | β9.1% | β15.0% | β24.6% | β7.3% | β16.6% |
Source: SEC EDGAR XBRL filings (CIK 0000882796). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
